The association of genetic testing timing and mutation type on breast cancer management in patients with breast cancer-related mutations

Ebunoluwa J. Olunuga,Samantha M. Thomas,Koumani W. Ntowe,Juliet C. Dalton,Ton Wang,Akiko Chiba,Jennifer K. Plichta

DOI: https://doi.org/10.1016/j.amjsurg.2024.116005

IF: 3.125

2024-10-07

The American Journal of Surgery

Abstract:(limit 150 wors) Background We aim to characterize breast management for patients with genetic mutations and concurrent breast cancer (BC) or prior BC treatment. Methods Adults with a BC-related mutation and prior/concurrent BC diagnosis were identified. Groups were stratified by mutation type [ BRCA1/2 , high penetrance mutation (HPM), moderate penetrance mutation (MPM)] and timing of genetic testing (concurrent with BC versus after BC treatment). Outcomes were compared. Results Among 338 patients included, 63% had BRCA1/2 mutations, 9% HPM, and 28% MPM. Approximately 38% had testing concurrent with a BC diagnosis and 62% after BC treatment. Patients with concurrent testing favored bilateral mastectomy (57%) versus 26% lumpectomy, and 16% unilateral mastectomy, which varied by mutation type. Patients previously treated preferred surveillance (92% vs. 8% additional surgery), regardless of mutation type. Conclusion The timing of a significant BC-related genetic test result and mutation type may be associated with management decisions among patients with breast cancer.

surgery